Skip to main content

Table 2 Inspiratory capacity on Day 1 and at Weeks 12 and 26 in the FAS population

From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

  Inspiratory capacity, L p-value
  NVA237 50 μg
(n = 534)
Placebo
(n = 260)
Difference  
Day 1     
   25 min 2.110 ± 0.0148 1.930 ± 0.0194 0.181 ± 0.0212 < 0.001
   1 h 55 min 2.166 ± 0.0157 1.978 ± 0.0210 0.189 ± 0.0230 < 0.001
   3 h 55 min 2.139 ± 0.0164 1.970 ± 0.0217 0.169 ± 0.0232 < 0.001
   23 h 40 min 2.019 ± 0.0168 1.915 ± 0.0222 0.104 ± 0.0239 < 0.001
Week 12     
   -20 min 1.967 ± 0.0221 1.883 ± 0.0281 0.084 ± 0.0286 0.003
   25 min 2.048 ± 0.0216 1.900 ± 0.0274 0.148 ± 0.0278 < 0.001
   1 h 55 min 2.103 ± 0.0232 1.923 ± 0.0297 0.180 ± 0.0305 < 0.001
   3 h 55 min 2.040 ± 0.0218 1.898 ± 0.0285 0.142 ± 0.0300 < 0.001
   23 h 40 min 2.009 ± 0.0212 1.912 ± 0.0282 0.097 ± 0.0296 < 0.001
Week 26     
   -20 min 1.988 ± 0.0202 1.879 ± 0.0267 0.109 ± 0.0281 < 0.001
   25 min 2.055 ± 0.0205 1.905 ± 0.0272 0.150 ± 0.0285 < 0.001
   1 h 55 min 2.107 ± 0.0214 1.929 ± 0.0288 0.178 ± 0.0309 < 0.001
   3 h 55 min 2.080 ± 0.0206 1.915 ± 0.0283 0.165 ± 0.0304 < 0.001
   23 h 40 min 1.997 ± 0.0192 1.884 ± 0.0257 0.113 ± 0.0275 < 0.001
  1. Values are least squares means ± standard errors